Completed PHASE4 INTERVENTIONAL 2-arm NCT03740958

Argatroban Plus R-tPA for Acute Ischemic Stroke

Argatroban Plus R-tPA for Acute Ischemic Stroke: a Prospective, Random, Open Label, Blinded Assessment of Outcome Multi-center Study

Sponsor: General Hospital of Shenyang Military Region

Conditions Stroke

Interventions Argatroban rt-PA

Updated 9 times since 2018 Last updated: Feb 20, 2022 Started: Dec 21, 2018 Primary completion: Jan 30, 2022 Completion: Jan 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Stroke and is currently completed. General Hospital of Shenyang Military Region leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2022 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Mar 2021 — Mar 2022 [monthly]

Recruiting PHASE4

▶ Show 4 earlier versions

Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE4
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE4
Jan 2019 — Feb 2020 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2018 — Jan 2019 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

General Hospital of Shenyang Military Region

Data source: General Hospital of Shenyang Military Region

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenyang, China